When Could Legend File Cilta-cel in 2L MM? Legend to Submit an NDA to Japan’s PMDA for Cilta-cel in R/R MM by YE 2021; Legend Develops a Novel Tri-Specific CAR-T; Legend Q3 2021 Earnings Summary
On Tuesday, November 16, Legend released their Q3 2021 financial updates (press release) highlighting that enrollment for cilta-cel’s (BCMA CAR-T) Ph3 CARTITUDE-4 study in 2-4L r/r MM has completed, while discussing cilta-cel’s FDA and PMDA regulatory updates. Additionally, management announced the development of LCAR-AIO, a novel tri-specific CD19 x CD20 x CD22 CAR-T for treating B-cell malignancies following CAR-T therapy relapse. Below, Celltelligence provides insights on when Legend / JNJ could potentially file cilta-cel’s sBLA in 2L r/r MM based on data from CARTITUDE-4, while discussing Legend’s novel tri-specific CAR-T and pipeline updates.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.